22 completed, 10 active not recruiting, 6 terminated, 3 withdrawn. 44 Phase 2, 8 Phase 1.
Follow Plasma Cell Myeloma: new trials by email Literature Review of Plasma Cell Myeloma trials Research Report on Plasma Cell Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant Belantamab Mafodotin, Lenalidomide - Plasma Cell Myeloma | Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 4 | 2024-08-19 | 2026-10-16 |
| International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone - Plasma Cell Myeloma | Phase 2 | Enrolling by invitation | Sanofi | 70 | 2023-04-05 | 2026-10-15 |
| Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Myeloma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 49 | 2022-08-11 | 2026-10-16 |
| Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma Belantamab Mafodotin, Dexamethasone, Pomalidomide - Plasma Cell Myeloma | Phase 2 | Recruiting | Emory University | 34 | 2022-07-21 | 2026-09-03 |
| Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy Pembrolizumab - Plasma Cell Myeloma | Phase 2 | Withdrawn | Emory University | 2022-04-11 | 2024-07-03 | |
| SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1 - COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm | Phase 2 | Active not recruiting | GeoVax, Inc. | 63 | 2021-09-27 | 2026-02-11 |
| Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma Selinexor, Dexamethasone Oral, Daratumumab - Multiple Myeloma, Myeloma Multiple | Phase 2 | Active not recruiting | US Oncology Research | 73 | 2021-09-10 | 2025-01-16 |
| Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy Xisomab 3G3 - Lymphoma, Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 9 | 2021-02-25 | 2024-01-24 |
| Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Myeloma, Renal Failure | Phase 2 | Terminated | Emory University | 17 | 2020-05-07 | 2024-07-01 |
| Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation Melphalan, Peripheral Blood Stem Cell Transplantation--CD34 HSCT, Peripheral Blood Stem Cell Transplantation--AHSCT - Plasma Cell Myeloma | Phase 2 | Terminated | University of Nebraska | 8 | 2020-01-09 | 2024-03-12 |
| Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Daratumumab, Laboratory Biomarker Analysis - Plasma Cell Myeloma, Secondary Amyloidosis | Phase 2 | Active not recruiting | City of Hope Medical Center | 31 | 2020-01-06 | 2026-10-20 |
| Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation Autologous Hematopoietic Stem Cell Transplantation, Filgrastim-sndz, Melphalan Hydrochloride - Plasma Cell Myeloma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 62 | 2019-10-09 | 2025-05-01 |
| Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant Anti-Thymocyte Globulin, Cyclophosphamide, Cytokine-treated Veto Cells - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 16 | 2019-08-08 | 2026-06-11 |
| Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Myeloma | Phase 2 | Unknown | Emory University | 49 | 2019-07-03 | 2024-06-21 |
| Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma Carfilzomib, Dexamethasone, Pomalidomide - Plasma Cell Myeloma | Phase 2 | Active not recruiting | Emory University | 29 | 2019-01-25 | 2025-04-30 |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients Carfilzomib, Daratumumab, Lenalidomide - Myeloma Multiple, Myeloma, Plasma-Cell | Phase 2 | Completed | Tel-Aviv Sourasky Medical Center | 41 | 2018-05-02 | 2022-01-27 |
| Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Daratumumab, Lenalidomide - Plasma Cell Myeloma | Phase 2 | Completed | Mayo Clinic | 49 | 2018-04-09 | 2026-05-05 |
| Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis Busulfan, Cyclophosphamide, Fludarabine - Anemia, ASXL1 Gene Mutation | Phase 2 | Terminated | University of Utah | 6 | 2018-03-30 | 2022-05-05 |
| Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Isatuximab SAR650984, Cemiplimab REGN2810 - Plasma Cell Myeloma | Phase 1 / Phase 2 | Completed | Sanofi | 109 | 2018-02-21 | 2024-06-14 |
| Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim - Plasma Cell Leukemia in Remission, Plasma Cell Myeloma | Phase 1 / Phase 2 | Withdrawn | City of Hope Medical Center | 2018-01-01 | 2017-12-13 |
Showing 20 of 44. Sign in to see all of them.
Multiple Myeloma (44) · Lymphoma, Non-Hodgkin (8) · Leukemia, Myeloid, Acute (7) · Hodgkin Disease (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Myelodysplastic Syndromes (6) · Anemia, Aplastic (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Myeloproliferative Disorders (4) · Primary Myelofibrosis (4) · Waldenstrom Macroglobulinemia (4) · Leukemia, Myeloid, Chronic-Phase (3) · Leukemia, Myelomonocytic, Chronic (3) · Lymphoma (3)
Blood Protein Disorders (44) · Cardiovascular Diseases (44) · Hematologic Diseases (44) · Hemic and Lymphatic Diseases (44) · Hemorrhagic Disorders (44) · Hemostatic Disorders (44) · Immune System Diseases (44) · Immunoproliferative Disorders (44) · Lymphoproliferative Disorders (44) · Neoplasms by Histologic Type (44) · Paraproteinemias (44) · Vascular Diseases (44) · Neoplasms (42) · Neoplasms, Plasma Cell (42) · Lymphatic Diseases (12)
Lenalidomide (17) · Dexamethasone (16) · Cyclophosphamide (11) · Calcium Dobesilate (10) · Melphalan (9) · daratumumab (9) · Peripheral Blood Stem Cell Transplantation (7) · Whole-Body Irradiation (7) · auricularum (7) · dexamethasone 21-phosphate (7) · dexamethasone acetate (7) · ixazomib (7) · Mycophenolic Acid (6) · Stem Cell Transplantation (6) · Bortezomib (5)
M.D. Anderson Cancer Center (6) · Mayo Clinic (6) · Emory University (5) · Fred Hutchinson Cancer Center (4) · Roswell Park Cancer Institute (3) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (3) · City of Hope Medical Center (2) · SWOG Cancer Research Network (2) · Sanofi (2) · GeoVax, Inc. (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1) · Tel-Aviv Sourasky Medical Center (1)
United States (43) · Italy (3) · Australia (2) · Brazil (2) · Czechia (2) · France (2) · Greece (2) · Spain (2) · Canada (1) · Chile (1) · China (1) · Denmark (1) · Finland (1) · Hungary (1) · Israel (1)
Ajay Nooka, MD, MPH (2) · Brenda Sandmaier (2) · Shaji Kumar (2) · Shaji Kumar, M.D. (2) · Ajay K Nooka, MD,MPH,FACP (1) · Ajay K. Nooka, MD,MPH,FACP (1) · Alexander Lesokhin, MD (1) · Amrita Y Krishnan (1) · Andrzej Jakubowiak (1) · Ann E. Dahlberg (1) · Catherine Lee, MD (1) · Choon-Kee Lee, MD (1) · Christopher D'Angelo, MD (1)
PMID 29246938, PMID 32603426, PMID 33619369, PMID 34048681, PMID 34182226, PMID 35285981, PMID 35737873, PMID 37970718, PMID 42537695
P30CA138292 (5), P30CA015704 (2), U10CA032102 (2), 2017 (1), 2023 (1), P01CA018029 (1), P01CA078902 (1), P30CA014599 (1), P30CA015083 (1), P30CA033572 (1), R01HL151367 (1)